Construction of a Prognostic Nomogram Model for Patients with Mucinous Breast Cancer

Table 1

Clinicopathological features of patients in modeling and validation group (case (%)).

Clinicopathological characteristics	Modeling group (n = 2776)		Validation group (n = 1188)
Age
18–39	116	4.1	44	3.7
40–59	772	27.8	326	27.4
60–79	1448	52.1	605	50.9
≥80	440	15.8	213	17.9
Ethnicity
White	2087	75.1	905	76.1
Black	343	12.3	144	12.1
Others	346	12.4	139	11.7
Marital status
Married	1418	51.0	608	51.1
Unmarried	1358	48.9	580	48.8
Lesion location
Left	1435	51.6	616	51.8
Right	1341	48.4	572	48.1
Histological grading
I	1644	59.2	710	59.7
II	1030	37.1	428	36.0
III	100	3, 6	49	4.1
IV	2	0.1	1	0.1
T Stage
T1	1776	63.9	795	66.9
T2	798	28.7	322	27.1
T3	153	5.5	56	4.7
T4	49	1.7	15	1.2
N Stage
N0	2506	90.2	1068	89.8
N1	216	7.7	101	8.5
N2	32	1.1	16	1.3
N3	22	0.7	3	0.2
M Stage
M0	2741	98.7	1174	98.8
M1	35	1.2	14	1.1
ER expression
Negative	36	1.2	10	0.8
Positive	2740	98.7	1178	99.1
PR expression
Negative	213	7.6	104	8.7
Positive	2563	92.3	1084	91.2
HER-2 expression
Negative	2614	94.1	1131	95.2
Positive	162	5.8	57	4.7
Surgery
Yes	2667	96.0	1150	96.8
None	109	3.9	38	3.1
Radiotherapy
Yes	1419	51.1	624	52.5
None	1357	48.8	564	47.4
Chemotherapy
Yes	381	13.7	157	13.2
None	2395	86.2	1031	86.7